Formulary Watch |

Genentech is conducting phase 3 trials of gantenerumab, an anti-amyloid antibody.

Investigators found only small differences in the change in LDL-C levels in the incentive groups versus the control group

Gavreto treats patients with advanced lung care and Arcalyst treats patients with recurrent pericarditis.

The labeling of Trikafta, which treats cystic fibrosis, has been updated to warn about the possibility of liver failure that could lead to the need for transplantation.

Talicia treats H. pylori infection, a risk factor for stomach cancer; Twirla is a hormonal contraceptive.

Merck plans to seek emergency use authorization for molnupiravir as the first oral treatment for COVID-19.

Three products, including Pfizer’s smoking cessation product Chantix, have been removed because generics are now available.

The labeling for selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake Inhibitors (SSNRIs) now must include information about sexual side effects in the warning and precautions and patient counseling sections.

Aetna, Cigna and UnitedHealthcare are enhancing their Medicare pharmacy benefits, including offering insulin for a copay of no more than $35 for a 30-day supply.

Given together, bamlanivimab and etesevimab have an emergency use authorization from the FDA to both treat COVID-19 and prevent infection in those who have been exposed.

Livmarli is the first drug approved for Alagille syndrome.

Effective Oct. 1, 2021, Aetna has added several cancer drugs to its formulary and has updated exclusions and nonpreferred products.

Comprehensive medication management aided by AI clinical decision support can result in a large return on investment in a high-risk population. In this study, every dollar that was invested resulted in $12 in savings or cost avoidance.